The Future Investor with Albert Anthony is an author concept launched on the Seeking Alpha platform, focusing on growing a diversified portfolio and unlocking future drivers of performance by covering stocks across multiple sectors.Albert Anthony is the pen name of a contributing analyst who has covered over +200 stocks on this platform since 2023, growing to over 1.07K followers. Based on this new article series, he is also working on a new book on Amazon to be called The Future Investor: Growing a Diversi ...

It's that time of year again. I'm not referring to buying gifts and preparing holiday meals -- although that may be part of your agenda too. It's time to look back on your portfolio's performance and plan for the year ahead.It's been a solid year for many, with all three indexes heading for triple-digit gains, and with the right mix of stocks, we might make 2025 a winning one too. Most importantly, though, remember to focus on the long term, as gains over a number of years are what we're really looking for ...

The year 2024 has been quite tumultuous for investors keen to invest their money in health technology companies. The year has seen AI-driven diagnostics and robotic-assisted surgeries being the two primary areas to lead the charge. Yet, despite the relentless spree of innovations in digital health, artificial intelligence (AI) and personalized medicine, the year also made the sector battle through significant healthcare labor shortages as well as supply challenges stemming from worldwide geopolitical issues ...

Abbott Laboratories’ (ABT) growth in the third quarter of 2024 can be attributed to strong sales recovery within the Nutrition business, driven by the robust sales performance of Ensure, the company’s market-leading complete and balanced nutrition brand. The company is driving solid growth in emerging markets within the EPD business. However, the runoff of COVID testing revenues and currency fluctuations may restrict Abbott’s growth potential.In the past year, this Zacks Rank #3 (Hold) company’s shares have ...

Abbott Laboratories, Inc. (ABT) has completed the world's first-in-human leadless left bundle branch area pacing (LBBAP) procedures. The landmark procedures were part of the prospective Leadless CSP (Conduction System Pacing) feasibility study, which evaluated the acute safety and performance of the company’s investigational AVEIR CSP leadless pacemaker system.The latest development is expected to strengthen Abbott’s Cardiac Rhythm Management business, part of the Medical Devices segment.ABT Stock’s Likely ...

Abbott's investigational AVEIR™ Conduction System Pacing (CSP) leadless pacemaker system is specifically designed to deliver pacing to the left bundle branch area, activating the heart's natural conduction system The device has received U.S. Food and Drug Administration Breakthrough Device Designation, which expedites the review of innovative technologies By creating a new pacing approach for the left bundle branch area of the heart, Abbott continues to pursue technologies to revolutionize care for people ...

Dividend increased by 7.3% Quarterly dividend payout has increased more than 60% since 2020 404th consecutive quarterly dividend to be paid by Abbott since 1924ABBOTT PARK, Ill., Dec. 13, 2024 /PRNewswire/ -- Abbott (NYSE: ABT) today announced that its board of directors has increased the company's quarterly common dividend to 59 cents per share, an increase of 7.3%. The company's quarterly dividend payout has increased more than 60% since 2020.This marks Abbott's 53rd consecutive year of dividend growth. ...

The latest trading session saw Abbott (ABT) ending at $118.77, denoting a -0.15% adjustment from its last day's close. The stock fell short of the S&P 500, which registered a gain of 0.56% for the day. At the same time, the Dow added 0.42%, and the tech-heavy Nasdaq gained 0.83%.Coming into today, shares of the maker of infant formula, medical devices and drugs had gained 4.92% in the past month. In that same time, the Medical sector lost 2.27%, while the S&P 500 gained 3.11%.Investors will be eagerly watch ...

Abbott Laboratories, Inc. (ABT) recently announced the first patient procedures with its investigational transcatheter aortic valve implantation (TAVI) balloon-expandable system for treating symptomatic severe aortic stenosis. The system is designed to build a foundation for artificial intelligence (AI) guided procedures. The investigational TAVI system will complement Abbott's Navitor TAVI system for aortic stenosis. The latest investigational TAVI system is aimed at expanding Abbott's structural heart por ...

The investigational transcatheter aortic valve implantation (TAVI) system will complement Abbott's Navitor™ TAVI system for aortic stenosis, a common and life-threatening heart valve disease The investigational system is designed to offer best-in-class heart blood flow, ease of use and precision Approximately 9% of older Americans have aortic stenosis1ABBOTT PARK, Ill., Nov. 25, 2024 /PRNewswire/ -- Abbott (NYSE: ABT) today announced the first patient procedures with its investigational transcatheter aorti ...